Medical Device Third-Party Logistics Market: as UPS Healthcare and DHL Group race through a compressed sequence of cold chain and specialty logistics acquisitions within a single year, the two largest global logistics companies are converging on the same strategic bet that healthcare represents their most durable growth vertical, so device and biologic manufacturers are watching their two largest carrier options consolidate specialty capability at a pace that leaves smaller regional 3PLs facing a narrowing window to remain relevant beyond geographic niches.

The global medical device third-party logistics market size was USD 14.84 Billion in 2025 and is expected to register a revenue CAGR of 7.8% during the forecast period. Market revenue growth is driven by factors such as cold chain infrastructure expansion required for biologics and temperature-sensitive device categories, the largest global logistics carriers consolidating specialty healthcare capability through acquisition, and healthcare revenue diversification strategy at the largest carriers accelerating capital investment into this vertical specifically. The first driving factor is cold chain infrastructure expansion, as biologics, cell and gene therapy products, and temperature-sensitive device categories require validated, continuous temperature-controlled logistics from manufacturing through point of use. Warehousing and storage services account for a substantial share of total 2025 market revenue, reflecting the centrality of GDP-compliant, temperature-controlled facilities to overall healthcare logistics infrastructure. The second driving factor is the largest global logistics carriers consolidating specialty healthcare capability through acquisition, converting general logistics infrastructure into dedicated, validated healthcare-specific networks. The third driving factor is healthcare revenue diversification strategy at the largest carriers, as UPS and DHL both target substantially higher healthcare-specific revenue as a share of total company revenue within defined multi-year timelines. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way a single carrier's acquisition of a specialised cold chain or regional logistics provider converts a general-purpose transportation network into a validated, healthcare-specific service capability, which lets that carrier capture a device or biologic manufacturer's entire specialty logistics spend within one commercial relationship rather than requiring the manufacturer to coordinate separate regional or temperature-specific vendors. Because biologic and temperature-sensitive device manufacturers increasingly prefer a single logistics partner capable of managing the full cold chain from manufacturing facility through final patient or provider delivery across multiple geographies, a carrier that acquires a specialised regional cold chain provider directly expands its addressable share of a manufacturer's total specialty logistics spend without requiring years of internal capability development. As a result, demand and revenue share are concentrating around the largest global carriers who can offer manufacturers single-relationship, multi-geography cold chain coverage, and the forecast tilts toward these consolidated networks rather than manufacturers coordinating separate regional specialty logistics vendors. For instance, in January 2025, UPS Healthcare completed its acquisitions of Frigo-Trans and BPL, extending its cold chain capability across the full temperature spectrum from cryopreservation to ambient conditions and creating a pan-European cold chain network as part of the company's strategy to double healthcare revenue from approximately USD 10 billion in 2023 to USD 20 billion by 2026. These are some of the key factors driving revenue growth of the market.

Because validated, GDP-compliant temperature-controlled logistics infrastructure requires substantial capital investment in specialised warehousing, transportation, and monitoring technology, smaller regional third-party logistics providers face a genuine capital barrier to competing for the highest-value biologic and cell and gene therapy logistics contracts that the largest carriers can pursue.

Integration complexity following rapid multi-carrier acquisition activity is a second constraint, because UPS Healthcare's and DHL Group's near-simultaneous acquisitions of multiple specialty logistics providers within a compressed timeframe create genuine operational integration challenges, including harmonising different providers' quality systems, technology platforms, and regional networks into a single coherent service offering.

Regulatory and customs complexity across multi-country cold chain shipments is a third constraint, since a single biologic or temperature-sensitive device shipment crossing multiple international borders must navigate varying import, customs, and healthcare product regulatory requirements at each jurisdiction, which adds coordination complexity and potential delay risk regardless of the underlying carrier's operational capability.

These factors substantially limit medical device third-party logistics market growth over the forecast period.

The clearest driver of demand is cold chain infrastructure expansion, as biologics, cell and gene therapy products, and temperature-sensitive device categories require validated, continuous temperature-controlled logistics from manufacturing through point of use. A break in temperature control anywhere along a biologic product's logistics chain can compromise the product's efficacy or safety entirely, so the infrastructure required to guarantee continuous validated temperature control represents genuine, non-negotiable capital investment rather than a discretionary service upgrade. Warehousing and storage services account for a substantial share of total 2025 market revenue, and in March 2025, DHL Group acquired CRYOPDP from Cryoport, adding cold chain logistics capability spanning 15 countries and more than 600,000 annual shipments for clinical trial, cell, and gene therapy applications. The effect on the market is that cold chain capacity has become a primary competitive battleground among the largest logistics carriers, directly tied to the growth of the biologic and advanced therapy product categories these carriers serve. These are some of the key factors driving revenue growth of the market.

The second driver is the largest global logistics carriers consolidating specialty healthcare capability through acquisition, converting general-purpose logistics infrastructure into dedicated, validated healthcare-specific networks. A device or biologic manufacturer coordinating logistics across multiple countries benefits significantly from a single carrier with an already-integrated, validated healthcare network rather than piecing together separate regional or specialty providers, so carriers that acquire regional specialty logistics providers directly expand their addressable healthcare-specific service offering. In April 2025, UPS Healthcare announced the USD 1.6 billion acquisition of Andlauer Healthcare Group, adding Canadian cold chain and Boyle Transportation capability, while DHL Group announced a USD 2.1 to 2.3 billion healthcare logistics investment commitment under its Strategy 2030 framework targeting global life sciences transformation. The effect on the market is that the competitive gap between the largest, most acquisitive carriers and smaller regional providers continues to widen as consolidation accelerates. These are some of the key factors driving revenue growth of the market.

UPS Healthcare's strategy targets doubling healthcare revenue from approximately USD 10 billion in 2023 to USD 20 billion by 2026. DHL Group has committed USD 2.1 to 2.3 billion in healthcare logistics investment under its Strategy 2030 framework. Both of the world's largest carriers are treating healthcare as their most consequential growth vertical.

The third driver is healthcare revenue diversification strategy at the largest carriers, as both UPS and DHL target substantially higher healthcare-specific revenue as a share of total company revenue within defined multi-year timelines. A logistics carrier facing margin pressure in commoditised general parcel and freight services has a direct financial incentive to shift capital investment toward healthcare logistics, where specialised validated capability commands meaningfully higher margins than general-purpose shipping, so publicly stated healthcare revenue targets function as a forcing mechanism for continued acquisition and capacity investment. In September 2025, DHL Group acquired SDS Rx, adding final-mile delivery services, specialty pharmacy delivery, and same-day capability to extend its end-to-end life sciences logistics offering beyond traditional warehousing and transportation. The effect on the market is that carrier capital allocation decisions increasingly favour healthcare-specific infrastructure and acquisition targets over general logistics capacity expansion. These are some of the key factors driving revenue growth of the market.

However, the medical device third-party logistics market faces severe adoption constraints from validated cold chain infrastructure capital costs that limit smaller provider competitiveness and integration complexity following rapid multi-carrier acquisition activity.

Because validated, GDP-compliant temperature-controlled logistics infrastructure requires substantial capital investment in specialised warehousing, transportation, and monitoring technology, smaller regional third-party logistics providers face a genuine capital barrier to competing for the highest-value biologic and cell and gene therapy logistics contracts that carriers with resources like UPS Healthcare and DHL Group can pursue.

Integration complexity following rapid multi-carrier acquisition activity compounds this, because UPS Healthcare's and DHL Group's near-simultaneous acquisitions of multiple specialty logistics providers within a compressed timeframe create genuine operational integration challenges, including harmonising different providers' quality systems, technology platforms, and regional networks into a single coherent service offering.

Regulatory and customs complexity across multi-country cold chain shipments is the third constraint, since a single biologic or temperature-sensitive device shipment crossing multiple international borders must navigate varying import, customs, and healthcare product regulatory requirements at each jurisdiction, which adds coordination complexity and potential delay risk regardless of the underlying carrier's operational capability.

These factors substantially limit medical device third-party logistics market growth over the forecast period.

Based on service, the global medical device third-party logistics market is segmented into warehousing and storage, transportation and distribution, and value-added services. Warehousing and storage holds the largest revenue share, because GDP-compliant, temperature-controlled facility capacity represents the foundational infrastructure investment underlying all downstream logistics services, which suits a market where facility-level capital investment commands the largest revenue category. Transportation and distribution remains an essential and closely sized second category, particularly for cold chain shipments requiring continuous monitoring in transit. Value-added services are expected to register the fastest revenue growth rate in the global medical device third-party logistics market over the forecast period, driven by DHL Group's SDS Rx acquisition extending final-mile and specialty pharmacy delivery capability.

Based on product, the global medical device third-party logistics market is segmented into IVD devices, high-value consumables, capital equipment, and surgical and sterile instruments. IVD devices hold the largest revenue share, because diagnostic device shipment volume, including temperature-sensitive reagent and test kit components, spans the broadest range of ongoing logistics demand relative to less frequently shipped capital equipment. High-value consumables are expected to register a significant revenue growth rate in the global medical device third-party logistics market over the forecast period, driven by expanding catheter, stent, and implantable device production volume requiring secure, traceable logistics handling.

Cold chain supply chain model is expected to register the fastest revenue growth rate in the global medical device third-party logistics market during the forecast period

Based on supply chain, the global medical device third-party logistics market is segmented into cold chain and non-cold chain models. Cold chain is expected to register the fastest revenue growth rate in the global medical device third-party logistics market over the forecast period, driven by UPS Healthcare's Frigo-Trans and BPL acquisitions extending temperature-controlled capability from cryopreservation through ambient conditions, and DHL Group's CRYOPDP acquisition adding cell and gene therapy cold chain capacity. Non-cold chain logistics remains the larger category by current volume, anchored by Class I device and general ambient-condition product shipments that do not require specialised temperature infrastructure.

Based on regional analysis, the medical device third-party logistics market in North America accounted for largest revenue share in 2025. The United States leads because the concentration of medical device and biologic manufacturer headquarters and the largest carrier commercial operations creates the deepest specialty logistics demand globally, and because UPS Healthcare, Cardinal Health, and FedEx Supply Chain all maintain their primary commercial presence in the US market. UPS Healthcare's Andlauer Healthcare Group acquisition specifically extends the company's North American cold chain network into Canada. Cardinal Health's OptiFreight logistics platform alone manages more than 22 million shipments annually across more than 25,000 shipping locations, reflecting the scale of the domestic specialty logistics relationship base.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, Switzerland, and the Netherlands represent significant national markets within Europe. UPS Healthcare's Frigo-Trans and BPL acquisitions specifically created a pan-European cold chain network, while Kuehne+Nagel's continued GxP facility expansion reinforces the region's established specialty logistics infrastructure. The result is steady rather than rapid growth, shaped more by EU regulatory and customs harmonisation than by underlying demand.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period. China and India represent two of the largest national markets within the region, driven by expanding medical device manufacturing capacity and rising healthcare logistics infrastructure investment. FedEx Supply Chain's Mumbai Life Science Center, inaugurated in February 2024, reflects continued regional infrastructure investment, leaving considerably more room for growth than in the already logistics-mature North American market.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national markets within the region, with expanding healthcare infrastructure driving early specialty logistics demand growth. The ongoing Iran-US sanctions and the resulting Strait of Hormuz shipping disruption have raised freight and fuel costs for the international shipping routes that Latin American cold chain logistics providers depend on, an effect expected to run through 2026 and slow medical device third-party logistics adoption beyond Brazil's and Mexico's main urban centres.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the UAE represent the primary commercial markets within the region. Saudi Arabia's expanding healthcare infrastructure investment and the UAE's regional distribution hub position represent the primary investment centres for medical device third-party logistics adoption. Saudi Arabia is the most established market on the continent, while the Gulf states outside it are still building the cold chain infrastructure needed to support advanced specialty logistics at scale.